Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway

Gao,Jun; Zhu,Hong; Wan,Hong; Zou,Xia; Ma,Xiaoxin; Gao,Guolan

doi:10.3892/or.2017.5952

Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK/CREB pathway

Authors:
- Jun Gao
- Hong Zhu
- Hong Wan
- Xia Zou
- Xiaoxin Ma
- Guolan Gao
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P.R. China, Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China, Department of Obstetrics and Gynecology, Aviation General Hospital of China Medical University, Beijing, P.R. China
Published online on: September 13, 2017 https://doi.org/10.3892/or.2017.5952
Pages: 2927-2934

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Ovarian cancer is the most lethal gynaecological cancer and the sixth most common cause of cancer related death among Western women. Recent studies show that harmine, a small-molecular β-carboline alkaloid present in medicinal plants, displayed obvious anticancer effects in several cancer cells. However, the effect of harmine on ovarian cancer is not well understood. In the present study, the effect of harmine on the cell proliferation and migration of ovarian cancer SKOV-3 cells and the underlying mechanism were investigated. Our results indicated that harmine significantly suppressed the proliferation of SKOV-3 cells in a dose-dependent manner. Interestingly, it also inhibited the epidermal growth factor (EGF)-induced proliferation of SKOV-3 cells. Moreover, the migration of SKOV-3 cells was markedly inhibited by harmine treatment. Further study showed that harmine inhibited not only the basal phosphorylation level of extracellular signal-regulated kinase 1/2 (ERK1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) but also EGF-induced ERK1/2 and CREB phosphorylation. Finally, harmine significantly suppressed the expression of vascular endothelial growth factor (VEGF) and matrix metalloproteinase (MMP) family MMP-2, and MMP-9. In conclusion, our data revealed that harmine inhibited the proliferation and migration of SKOV-3 cells, which might be mediated by ERK/CREB pathway. These findings elucidate that harmine may act as a potential therapeutic drug for ovarian cancer treatment.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Coleman RL, Monk BJ, Sood AK and Herzog TJ: Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 10:211–224. 2013. View Article : Google Scholar : PubMed/NCBI
3	Mukherjee AK, Basu S, Sarkar N and Ghosh AC: Advances in cancer therapy with plant based natural products. Curr Med Chem. 8:1467–1486. 2001. View Article : Google Scholar : PubMed/NCBI
4	McChesney JD: Natural products in drug discovery - organizing for success. P R Health Sci J. 21:91–95. 2002.PubMed/NCBI
5	Cragg GM, Newman DJ and Snader KM: Natural products in drug discovery and development. J Nat Prod. 60:52–60. 1997. View Article : Google Scholar : PubMed/NCBI
6	Cao R, Peng W, Wang Z and Xu A: beta-Carboline alkaloids: Biochemical and pharmacological functions. Curr Med Chem. 14:479–500. 2007. View Article : Google Scholar : PubMed/NCBI
7	Patel K, Gadewar M, Tripathi R, Prasad SK and Patel DK: A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid ‘Harmine’. Asian Pac J Trop Biomed. 2:660–664. 2012. View Article : Google Scholar : PubMed/NCBI
8	Farzin D and Mansouri N: Antidepressant-like effect of harmane and other beta-carbolines in the mouse forced swim test. Eur Neuropsychopharmacol. 16:324–328. 2006. View Article : Google Scholar : PubMed/NCBI
9	Cao MR, Li Q, Liu ZL, Liu HH, Wang W, Liao XL, Pan YL and Jiang JW: Harmine induces apoptosis in HepG2 cells via mitochondrial signaling pathway. Hepatobiliary Pancreat Dis Int. 10:599–604. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hamsa TP and Kuttan G: Harmine activates intrinsic and extrinsic pathways of apoptosis in B16F-10 melanoma. Chin Med. 6:112011. View Article : Google Scholar : PubMed/NCBI
11	Zhang P, Huang CR, Wang W, Zhang XK, Chen JJ, Wang JJ, Lin C and Jiang JW: Harmine hydrochloride triggers G2 phase arrest and apoptosis in MGC-803 cells and SMMC-7721 cells by upregulating p21, activating caspase-8/Bid, and downregulating ERK/Bad pathway. Phytother Res. 30:31–40. 2016. View Article : Google Scholar : PubMed/NCBI
12	Lafky JM, Wilken JA, Baron AT and Maihle NJ: Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta. 1785:232–265. 2008.PubMed/NCBI
13	Liu LZ, Hu XW, Xia C, He J, Zhou Q, Shi X, Fang J and Jiang BH: Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med. 41:1521–1533. 2006. View Article : Google Scholar : PubMed/NCBI
14	Newby AC: Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 69:614–624. 2006. View Article : Google Scholar : PubMed/NCBI
15	Bernatchez PN, Soker S and Sirois MG: Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem. 274:31047–31054. 1999. View Article : Google Scholar : PubMed/NCBI
16	Demain AL and Vaishnav P: Natural products for cancer chemotherapy. Microb Biotechnol. 4:687–699. 2011. View Article : Google Scholar : PubMed/NCBI
17	Kummar S, Gutierrez M, Doroshow JH and Murgo AJ: Drug development in oncology: Classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol. 62:15–26. 2006. View Article : Google Scholar : PubMed/NCBI
18	Fox E, Curt GA and Balis FM: Clinical trial design for target-based therapy. Oncologist. 7:401–409. 2002. View Article : Google Scholar : PubMed/NCBI
19	Dakic V, Maciel RM, Drummond H, Nascimento JM, Trindade P and Rehen SK: Harmine stimulates proliferation of human neural progenitors. PeerJ. 4:e27272016. View Article : Google Scholar : PubMed/NCBI
20	Hämmerle B, Ulin E, Guimera J, Becker W, Guillemot F and Tejedor FJ: Transient expression of Mnb/Dyrk1a couples cell cycle exit and differentiation of neuronal precursors by inducing p27KIP1 expression and suppressing NOTCH signaling. Development. 138:2543–2554. 2011. View Article : Google Scholar : PubMed/NCBI
21	Seshacharyulu P, Ponnusamy MP, Haridas D, Jain M, Ganti AK and Batra SK: Targeting the EGFR signaling pathway in cancer therapy. Expert Opin Ther Targets. 16:15–31. 2012. View Article : Google Scholar : PubMed/NCBI
22	Dimova I, Zaharieva B, Raitcheva S, Dimitrov R, Doganov N and Toncheva D: Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors. Int J Gynecol Cancer. 16:145–151. 2006. View Article : Google Scholar : PubMed/NCBI
23	Dancey JE and Freidlin B: Targeting epidermal growth factor receptor - are we missing the mark? Lancet. 362:62–64. 2003. View Article : Google Scholar : PubMed/NCBI
24	Lassus H, Sihto H, Leminen A, Joensuu H, Isola J, Nupponen NN and Butzow R: Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl). 84:671–681. 2006. View Article : Google Scholar : PubMed/NCBI
25	Aggarwal S, Kim SW, Ryu SH, Chung WC and Koo JS: Growth suppression of lung cancer cells by targeting cyclic AMP response element-binding protein. Cancer Res. 68:981–988. 2008. View Article : Google Scholar : PubMed/NCBI
26	Lu P, Weaver VM and Werb Z: The extracellular matrix: A dynamic niche in cancer progression. J Cell Biol. 196:395–406. 2012. View Article : Google Scholar : PubMed/NCBI
27	Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2:161–174. 2002. View Article : Google Scholar : PubMed/NCBI
28	Gomez DE, Alonso DF, Yoshiji H and Thorgeirsson UP: Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol. 74:111–122. 1997.PubMed/NCBI
29	Hu P, He J, Liu S, Wang M, Pan B and Zhang W: β2-adrenergic receptor activation promotes the proliferation of A549 lung cancer cells via the ERK1/2/CREB pathway. Oncol Rep. 36:1757–1763. 2016. View Article : Google Scholar : PubMed/NCBI